Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer Disease: early-phase trial registry
155 of 312 indexed Alzheimer Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #25 of 28,707 conditions by registered trial count.
312 US clinical trials · 155 currently recruiting · #25 of 28,707 conditions by registered trial count
Alzheimer Disease: 312 US clinical trials tracked, 155 recruiting.
Alzheimer Disease is the subject of 312 registered US clinical trials on ClinicalTrials.gov, 155 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 13 of these trials.
Enrollment posture brief
Registry condition alzheimer-disease
OPEN 155 | RECR 50% | LATE 26 | EARLY 104 | RANK #25 | SPON 13
Volume-matched condition peers
Nearest open-share peer: PTSD (50% recruiting · 155 trials)
Alzheimer Disease lists 155 open slots (50% of 312 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer Disease is recruiting above its size-band peers.
155 of 312 indexed trials (49.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimer Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 13 of 312 trials (4.2%). 178 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimer Disease enrolment sits around 100 participants.
Median target enrolment is 100 among the 307 trials that report a genuine target (sentinel values excluded). 151 of those (49.2%) plan for fewer than 100 participants.
-
Alzheimer Disease research is mostly interventional.
255 interventional and 57 observational studies make up this index (81.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
312 total, page 6 of 7
A Phase I Study for Safety and Tolerability of AL002.
Alector
NCT03635047
Eye to Brain Connection
Optina Diagnostics
NCT05215782
A Study of LY3002813 in Participants With Alzheimer's Disease
Eli Lilly and Company
NCT01837641
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
Eli Lilly and Company
NCT02624778
Acute Exercise and the Cerebral Metabolic Response in Aging and Alzheimer's Disease
University of Kansas Medical Center
NCT04299308
Powerful Tools for Caregivers of Dementia Patients
Florida State University
NCT02697721
11C-PIB PET Study in MESA at Columbia University
José A. Luchsinger
NCT03981380
Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers
Neuronascent
NCT04074837
Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans
Tammie L. S. Benzinger, MD, PhD
NCT03287765
Telehealth-enabled Integrated Palliative Care for People With Dementia
Thomas Jefferson University
NCT05524181
Telomerase Activator and Retinal Amyloid
Chippewa Valley Eye Clinic
NCT02530255
SNIFF - Combo INI+EMPA Trial
Wake Forest University Health Sciences
NCT05081219
Effect of CT1812 Treatment on Brain Synaptic Density
Cognition Therapeutics
NCT03493282
Salsalate in Patients Mild to Moderate Alzheimer's Disease
Adam Boxer
NCT03277573
Brain Imaging in Alzheimer's Disease
National Institute of Mental Health (NIMH)
NCT00039702
Assessing a Novel Virtual Environment That Assists With Activities of Daily Living
mandy
NCT05418296
Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects
Avid Radiopharmaceuticals
NCT04474405
Virtual Reality Cognitive Therapy for Alzheimer's Disease
Claritytek
NCT05788848
At-Home Telehealth Yoga for Treating Chronic Pain in People With Alzheimer's Disease and Their Caregiver's
Palo Alto Veterans Institute for Research
NCT04512040
Socially Isolated Older Adults Living With Dementia
University of Washington
NCT03666624
Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
Bristol-Myers Squibb
NCT00860275
The Cognitive Resilience Study
Duke University
NCT03016702
Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD
NYU Langone Health
NCT03389698
Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease
Institute for Neurodegenerative Disorders
NCT00480701
Movement Intervention for Memory Enhancement
Albert Einstein College of Medicine
NCT03475316
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
University of Southern California
NCT02221622
Brain Vascular and Neurocognitive Health
The University of Texas at Arlington
NCT06497413
A Safety Study of PTI-125 in Healthy Volunteers
Pain Therapeutics
NCT03784300
Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00795730
Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Alzheimer Disease
University of Pennsylvania
NCT04482179
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Institute for Neurodegenerative Disorders
NCT00556660
A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
Avid Radiopharmaceuticals
NCT01565330
Zolpidem CR and Hospitalized Patients With Dementia
Massachusetts General Hospital
NCT00814502
Improving Sleep and Cognition in Alzheimer's Disease
Emory University
NCT05200208
Rhythmically Entrained Exercise in Community-Dwelling Older Adults
University of North Carolina, Greensboro
NCT05462977
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
Massachusetts General Hospital
NCT05189106
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Rural Homes
University of California, Berkeley
NCT05159583
A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD
Steven E Arnold, MD
NCT05004688
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
Pfizer
NCT00788047
Our Care Wishes - Dementia
University of Pennsylvania
NCT05033262
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
Northwell Health
NCT00551161
Network Modulation in Alzheimer's Disease
Brigham and Women's Hospital
NCT04045990
Treatment of Language and Memory in Patients With Alzheimer's Disease
University of Arkansas
NCT00593372
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
VA Office of Research and Development
NCT00385684
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
Invicro
NCT03071224
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
The University of Texas Health Science Center at San Antonio
NCT04200911
Imaging Inflammation in Alzheimer's Disease With 11C-ER176
Columbia University
NCT03744312
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Eisai
NCT04971733
Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease
NeuroEM Therapeutics
NCT02958930
Alzheimer's Disease Stem Cells Multiple Infusions
Bernard (Barry) Baumel
NCT04040348
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 51 |
| Phase 3 | 18 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer Disease page
312 registered trials, 155 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 155 Alzheimer Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Alzheimer Disease trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease condition card totals 312 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.